These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21726264)

  • 1. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.
    Fung RK; Kerridge IH
    Bioethics; 2013 Feb; 27(2):89-96. PubMed ID: 21726264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A challenge towards the clinical application of induced pluripotent stem cell technology for the treatment of Parkinson's disease].
    Morizane A; Takahashi J
    Brain Nerve; 2012 Jan; 64(1):29-37. PubMed ID: 22223499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethics and stem cell therapeutics for cardiovascular disease.
    Sugarman J
    Prog Cardiovasc Dis; 2007; 50(1):1-6. PubMed ID: 17631433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational prospects for human induced pluripotent stem cells.
    Csete M
    Regen Med; 2010 Jul; 5(4):509-19. PubMed ID: 20632855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ethical reflections on cell reprogramming].
    Aznar Lucea J; Martínez M
    Cuad Bioet; 2012; 23(78):287-99. PubMed ID: 23130744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening.
    Song M; Paul S; Lim H; Dayem AA; Cho SG
    Arch Pharm Res; 2012 Feb; 35(2):245-60. PubMed ID: 22370779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A commentary on iPS cells: potential applications in autologous transplantation, study of illnesses and drug screening.
    Romano G; Morales F; Marino IR; Giordano A
    J Cell Physiol; 2014 Feb; 229(2):148-52. PubMed ID: 23881704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human cell transplant trials in Parkinson's disease: The need for an improved informed consent process.
    de Melo-Martín I; Hellmers N; Henchcliffe C
    Parkinsonism Relat Disord; 2015 Aug; 21(8):829-32. PubMed ID: 26004682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotent stem cells and promises of neuroregenerative medicine.
    Verma A; Verma N
    Neurol India; 2011; 59(4):555-7. PubMed ID: 21891933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced pluripotent stem cell-derived hepatocytes as an alternative to human adult hepatocytes.
    Katsuda T; Sakai Y; Ochiya T
    J Stem Cells; 2012; 7(1):1-17. PubMed ID: 23550341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A natural stem cell therapy? How novel findings and biotechnology clarify the ethics of stem cell research.
    Patel P
    J Med Ethics; 2006 Apr; 32(4):235-9. PubMed ID: 16574879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine first-in-human research: challenges for informed consent.
    King NM
    J Law Med Ethics; 2012; 40(4):823-30. PubMed ID: 23289684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling human neurological disorders with induced pluripotent stem cells.
    Imaizumi Y; Okano H
    J Neurochem; 2014 May; 129(3):388-99. PubMed ID: 24286589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
    Carpenter MK; Couture LA
    Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bench to bedside and to health policies: ethics in translational research.
    Petrini C
    Clin Ter; 2011; 162(1):51-9. PubMed ID: 21448547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells.
    Kumar D; Anand T; Kues WA
    Cell Biol Toxicol; 2017 Apr; 33(2):99-112. PubMed ID: 27900567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethics, ambiguity aversion, and the review of complex translational clinical trials.
    Kimmelman J
    Bioethics; 2012 Jun; 26(5):242-50. PubMed ID: 21241343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the Moral Status of iPS Cells.
    Martinho AM
    New Bioeth; 2016 Jul; 22(2):148-154. PubMed ID: 28219287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to induced pluripotent stem cells.
    Hanley J; Rastegarlari G; Nathwani AC
    Br J Haematol; 2010 Oct; 151(1):16-24. PubMed ID: 20666774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of clinically relevant "induced pluripotent stem" (iPS) cells.
    Heffernan C; Sumer H; Verma PJ
    J Stem Cells; 2011; 6(3):109-27. PubMed ID: 23264997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.